Navigation Links
Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
Date:7/16/2008

Raptor to Support Phase 2a Clinical Trial at UCSD

NOVATO, Calif., July 16 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the execution of a collaboration agreement (the "Agreement") with the University of California, San Diego ("UCSD") to include a Phase 2a clinical trial to evaluate a delayed-release preparation of cysteamine bitartrate ("Cysteamine") in adolescents diagnosed with Non-Alcoholic Steatohepatitis ("NASH"). NASH is a progressive form of liver disease that accounts for approximately 10% of newly diagnosed cases of chronic liver disease, and ranks as one of the leading causes of cirrhosis of the liver in the U.S.

Under the terms of the Agreement, clinical researchers from UCSD will perform the Phase 2a study at the University's General Clinical Research Center, and Raptor will provide funding and clinical supply of Cysteamine. In March 2008, Raptor acquired an exclusive, worldwide license to certain intellectual property and development rights from UCSD surrounding the use of Cysteamine as a potential treatment for NASH.

A rapid-release form of Cysteamine is currently approved for sale by the U.S. Food and Drug Administration ("FDA") for the treatment of nephropathic cystinosis, a rare, genetic lysosomal storage disease. Raptor is currently developing DR Cysteamine, a proprietary, delayed-release formulation of Cysteamine, designed to improve bioavailability and potentially reduce side effects associated with the presently marketed form.

Ted Daley, President of Raptor's clinical division stated, "We look forward to working with UCSD, one of the leading research universities in the nation, under this collaboration agreement. The University's clinical researchers have specific expertise in treating NASH patients, and have also worked extensively with Cysteamine. We are fortunate to work with this team to investigate our drug candidate
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
2. Raptor Pharmaceuticals Provides Update of Product Programs
3. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
4. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
5. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
6. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
7. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
10. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
11. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)...clinical program to evaluate TAXUS(R) Element(TM) ...Stent, NATICK, Mass., Oct. 8 /PRNewswire-FirstCal...today announced that it has completed enrollment i...any,s third-generation,TAXUS(R) Element(TM) paclit...program has enrolled nearly 1,500 patients at 100 ...
(Date:10/7/2008)...DIEGO, Oct. 7 /- Prometheus Laborator...y announced findings from its,development of PROME...test,for irritable bowel syndrome (IBS). The findi...on of particular biomarkers in blood samples,betwe... these biomarkers,combined with a proprietary alg...
(Date:10/7/2008)...lts of FLEXX Trial Presented at the Osteoarthritis...ess, PARSIPPANY, N.J., Oct. 7 /- Fer...ts from the FLEXX Trial of Osteoarthritis of the,K...te), a highly pure,non-avian high molecular weight...is superior to intra-articular saline (IA-saline) ...
(Date:10/7/2008)... clinical study of adults, VYVANSE taken once-dail...in one week, PHILADELPHIA, Oct. 7 /PRNewswire-Fir...e global specialty biopharmaceutical company, toda...r issue of the Journal of,Clinical Psychiatry foun...ion Deficit Hyperactivity Disorder (ADHD) symptoms...
Breaking Medicine Technology:Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Tongji Hires German Based Dr Petri Consulting GmbH for Langdong Project 24446 1Tongji Hires German Based Dr Petri Consulting GmbH for Langdong Project 24446 2Psychemedics Corporation Announces Second Quarter Results 24442 1Psychemedics Corporation Announces Second Quarter Results 24442 2Psychemedics Corporation Announces Second Quarter Results 24442 3Psychemedics Corporation Announces Second Quarter Results 24442 4Psychemedics Corporation Announces Second Quarter Results 24442 5Arcadia Radiology Medical Group Chooses AMICAS 6758 1Arcadia Radiology Medical Group Chooses AMICAS 6758 2Arcadia Radiology Medical Group Chooses AMICAS 6758 3Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 1Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 2Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 3Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 4
...pyridopyrazine-urea derivative compound series sho...e valuable for cancer,treatment , , QUBEC C... (TSX: AEZ; Nasdaq:,AEZS), a global, pure play b...erapy and oncology, today presented an abstract,...e derivatives,with high selectivity for PI3K inh...
...SINESS WIRE)--Apr 17, 2007 - Alnylam,Pharmaceutica...cs,company, announced today at the American Associ...ng that it will advance a,systemically delivered R...iver cancer and potentially other solid tumors as ...erapeutic that is,designed to target vascular endo...
Other Medicine Technology:terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 2terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 3terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 4Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 2Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 3Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 4Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 5
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
... nonsurgical image-guided treatment of kidney tumo...copic// technique in viable candidates. The resear...Radiology’s 32nd Annual Scientific Meeting. The ...ous cryoablation results in a slightly lower recur...
...s to help stroke survivors with the kind of comple...outside the box," according// to a University of I...participants' abilities were independent of any ch...improvements in complex mental abilities were not ...
...n are at a higher risk of perinatal mortality (dea...ies born to black or white women// , concludes a s... Health Organisation defines post-term pregnancy a...irst day of the last menstrual period. Post-term p...
...orld's largest maker of generic drugs and 19 other...ine medicines without federal approval. The Food ...s were part of an effort to halt the marketing of ...drugs. The goal is to get the unapproved drugs off...
Other Medicine News:Health News:Freezing Kidney Tumors Effective and Less Expensive Than Laparoscopy 2Health News:Antidepressants Improve Post-Stroke Mental Abilities 2Health News:Antidepressants Improve Post-Stroke Mental Abilities 3Health News:FDA Warns Migraine Medicine Makers 2
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer
...al growth system, combines orbital shaking, oxygen...r bacterial growth. It is designed for easy integr...Extractor. The uniquely engineered HT-MegaGrowTM h...akers. Plate-holding cassettes allow for high plat...
Inquire
Inquire
Medicine Products: